title: Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.
abstract: National attention continues to focus on the need to improve care for individuals with co-occurring mental illnesses and substance use disorders, as emphasized in the 2003 President's New Freedom Commission Report on Mental Health and recent publications from the Substance Abuse and Mental Health Services Administration (SAMHSA). These reports document the need for best practice recommendations that can be translated into routine clinical care. Although efforts are underway to synthesize literature in this area, few focused recommendations are available that include expert opinion and evidence-based findings on the management of specific co-occurring disorders, such as schizophrenia and addiction. In response to the need for user-friendly recommendations on the treatment of schizophrenia and addiction, a consensus conference of experts from academic institutions and state mental health systems was organized to 1) frame the problem from clinical and systems-level perspectives; 2) identify effective and problematic psychosocial, pharmacological, and systems practices; and 3) develop a summary publication with recommendations for improving current practice. The results of the consensus meeting served as the foundation for this publication, which presents a broad set of recommendations for clinicians who treat individuals with schizophrenia. "Integrated treatment" is the new standard for evidence-based treatment for this population and recommendations are given to help clinicians implement such integrated treatment. Specific recommendations are provided concerning screening for substance use disorders in patients with schizophrenia, assessing motivation for change, managing medical conditions that commonly occur in patients with dual diagnoses (e.g., cardiovascular disease, liver complications, lung cancer, HIV, and hepatitis B or C infections) and selecting the most appropriate medications for such patients to maximize safety and minimize drug interactions, use of evidence-based psychosocial interventions for patients with dual diagnoses (e.g., Dual Recovery Therapy, modified cognitive-behavioral therapy, modified motivational enhancement therapy, and the Substance Abuse Management Module), and key pharmacotherapy principles for treating schizophrenia, substance use disorders, and comorbid anxiety, depression, and sleep problems in this population. Finally the article reviews programmatic and systemic changes needed to overcome treatment barriers and promote the best outcomes for this patient population. An algorithm summarizing the consensus recommendations is provided in an appendix.
authors.affiliation: University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 675 Hoes Lane, Rm. D-349, Piscataway, NJ 08854, USA.
authors.forename: Douglas M
authors.initials: DM
authors.lastname: Ziedonis
authors.forename: David
authors.initials: D
authors.lastname: Smelson
authors.forename: Richard N
authors.initials: RN
authors.lastname: Rosenthal
authors.forename: Steven L
authors.initials: SL
authors.lastname: Batki
authors.forename: Alan I
authors.initials: AI
authors.lastname: Green
authors.forename: Renata J
authors.initials: RJ
authors.lastname: Henry
authors.forename: Ivan
authors.initials: I
authors.lastname: Montoya
authors.forename: Joseph
authors.initials: J
authors.lastname: Parks
authors.forename: Roger D
authors.initials: RD
authors.lastname: Weiss
mesh_terms: D000465:Algorithms; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D017831:Diagnosis, Dual (Psychiatry); D004347:Drug Interactions; D019317:Evidence-Based Medicine; D006801:Humans; D008605:Mental Health Services / Q000458:organization & administration; D011787:Quality of Health Care; D012559:Schizophrenia / Q000150:complications* / Q000628:therapy*; D019966:Substance-Related Disorders / Q000150:complications* / Q000628:therapy*
chemical_list: D014150:Antipsychotic Agents